JP6720079B2 - 対象とするヒト標的に特異的に結合するリガンド - Google Patents

対象とするヒト標的に特異的に結合するリガンド Download PDF

Info

Publication number
JP6720079B2
JP6720079B2 JP2016541434A JP2016541434A JP6720079B2 JP 6720079 B2 JP6720079 B2 JP 6720079B2 JP 2016541434 A JP2016541434 A JP 2016541434A JP 2016541434 A JP2016541434 A JP 2016541434A JP 6720079 B2 JP6720079 B2 JP 6720079B2
Authority
JP
Japan
Prior art keywords
human
toi
antibody
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502030A (ja
Inventor
ジャスパー・クリューブ
Original Assignee
カイマブ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1322250.0A external-priority patent/GB2521355A/en
Priority claimed from GB1322253.4A external-priority patent/GB2521356B/en
Priority claimed from US14/138,446 external-priority patent/US8883157B1/en
Priority claimed from EP14172578.8A external-priority patent/EP2886557A1/de
Priority claimed from US14/331,609 external-priority patent/US9051378B1/en
Priority claimed from US14/331,730 external-priority patent/US9914769B2/en
Priority claimed from US14/331,665 external-priority patent/US9023359B1/en
Priority claimed from US14/457,536 external-priority patent/US9017678B1/en
Priority claimed from US14/457,566 external-priority patent/US8945560B1/en
Priority claimed from US14/472,828 external-priority patent/US8986691B1/en
Priority claimed from US14/472,685 external-priority patent/US8992927B1/en
Priority claimed from US14/472,698 external-priority patent/US8986694B1/en
Priority claimed from US14/472,818 external-priority patent/US8980273B1/en
Priority claimed from EP14185297.0A external-priority patent/EP2975058A1/de
Priority claimed from US14/500,233 external-priority patent/US9045548B1/en
Priority claimed from US14/507,368 external-priority patent/US9034332B1/en
Priority claimed from US14/536,049 external-priority patent/US9045545B1/en
Priority claimed from US14/537,403 external-priority patent/US9067998B1/en
Application filed by カイマブ・リミテッド filed Critical カイマブ・リミテッド
Priority claimed from PCT/GB2014/053729 external-priority patent/WO2015092393A2/en
Publication of JP2017502030A publication Critical patent/JP2017502030A/ja
Application granted granted Critical
Publication of JP6720079B2 publication Critical patent/JP6720079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016541434A 2013-12-17 2014-12-17 対象とするヒト標的に特異的に結合するリガンド Active JP6720079B2 (ja)

Applications Claiming Priority (67)

Application Number Priority Date Filing Date Title
US201361916866P 2013-12-17 2013-12-17
US201361916862P 2013-12-17 2013-12-17
GB1322250.0A GB2521355A (en) 2013-12-17 2013-12-17 Human targets I
GB1322250.0 2013-12-17
GB1322253.4 2013-12-17
US61/916,862 2013-12-17
US61/916,866 2013-12-17
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
US14/138,446 US8883157B1 (en) 2013-12-17 2013-12-23 Targeting rare human PCSK9 variants for cholesterol treatment
US14/138,446 2013-12-23
US14/228,760 US8951523B1 (en) 2013-12-17 2014-03-28 Targeting rare human PCSK9 variants for cholesterol treatment
US14/228,760 2014-03-28
EP14172578.8 2014-06-16
EP14172578.8A EP2886557A1 (de) 2013-12-17 2014-06-16 Antikörper zur Anwendung bei der Behandlung von spezifischen PCSK9 Varianten bezüglich Erkrankungen bei spezifischen Patientengruppen
EP14172579.6 2014-06-16
EP14172579.6A EP2886558A1 (de) 2013-12-17 2014-06-16 Antikörper zur Anwendung bei der Behandlung von spezifischen PCSK9 Varianten bezüglich Erkrankungen bei spezifischen Patientengruppen
US14/331,665 US9023359B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/331,730 US9914769B2 (en) 2014-07-15 2014-07-15 Precision medicine for cholesterol treatment
US14/331,730 2014-07-15
US14/331,609 2014-07-15
US14/331,665 2014-07-15
US14/331,609 US9051378B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/457,536 2014-08-12
US14/457,566 2014-08-12
US14/457,566 US8945560B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/457,536 US9017678B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/472,828 2014-08-29
US14/472,818 2014-08-29
US14/472,698 2014-08-29
US14/472,685 2014-08-29
US14/472,685 US8992927B1 (en) 2014-07-15 2014-08-29 Targeting human NAV1.7 variants for treatment of pain
US14/472,698 US8986694B1 (en) 2014-07-15 2014-08-29 Targeting human nav1.7 variants for treatment of pain
US14/472,818 US8980273B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,828 US8986691B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/490,160 US8999341B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,091 2014-09-18
US14/490,091 US9068012B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,112 2014-09-18
EP14185297.0 2014-09-18
US14/490,175 US9040052B1 (en) 2013-12-17 2014-09-18 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14185297.0A EP2975058A1 (de) 2014-07-15 2014-09-18 Antikörper zur Anwendung bei der Behandlung von spezifischen PCSK9 Varianten bezüglich Erkrankungen bei spezifischen Patientengruppen
US14/490,160 2014-09-18
US14/490,175 2014-09-18
US14/490,112 US9034331B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/500,397 US10618971B2 (en) 2013-12-17 2014-09-29 Targeting rare human PCSK9 variants for cholesterol treatment
US14/500,233 2014-09-29
US14/500,233 US9045548B1 (en) 2014-07-15 2014-09-29 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/500,397 2014-09-29
US14/507,368 2014-10-06
US14/507,368 US9034332B1 (en) 2014-07-15 2014-10-06 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14190945 2014-10-29
EP14190945.7 2014-10-29
US14/536,049 US9045545B1 (en) 2014-07-15 2014-11-07 Precision medicine by targeting PD-L1 variants for treatment of cancer
US14/536,129 2014-11-07
US14/536,129 US9062105B1 (en) 2014-07-15 2014-11-07 Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US14/536,049 2014-11-07
US14/537,403 US9067998B1 (en) 2014-07-15 2014-11-10 Targeting PD-1 variants for treatment of cancer
US14/537,403 2014-11-10
US14/552,816 2014-11-25
US14/552,816 US10611849B2 (en) 2013-12-17 2014-11-25 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14196641 2014-12-05
EP14196638 2014-12-05
EP14196641.6 2014-12-05
EP14196645 2014-12-05
EP14196645.7 2014-12-05
EP14196638.2 2014-12-05
PCT/GB2014/053729 WO2015092393A2 (en) 2013-12-17 2014-12-17 Human targets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020104523A Division JP2020152729A (ja) 2013-12-17 2020-06-17 対象とするヒト標的に特異的に結合するリガンド

Publications (2)

Publication Number Publication Date
JP2017502030A JP2017502030A (ja) 2017-01-19
JP6720079B2 true JP6720079B2 (ja) 2020-07-08

Family

ID=56800882

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541434A Active JP6720079B2 (ja) 2013-12-17 2014-12-17 対象とするヒト標的に特異的に結合するリガンド
JP2020104523A Pending JP2020152729A (ja) 2013-12-17 2020-06-17 対象とするヒト標的に特異的に結合するリガンド
JP2021155708A Active JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020104523A Pending JP2020152729A (ja) 2013-12-17 2020-06-17 対象とするヒト標的に特異的に結合するリガンド
JP2021155708A Active JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Country Status (3)

Country Link
JP (3) JP6720079B2 (de)
CN (1) CN106062004A (de)
DE (2) DE112014005747T5 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US11566073B2 (en) * 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
CN108034712A (zh) * 2017-12-28 2018-05-15 上海市儿童医院 川崎病冠状动脉病变风险诊断与检测试剂盒
SG11202008848XA (en) * 2018-03-26 2020-10-29 Regeneron Pharma Anti-pfrh5 antibodies and antigen-binding fragments thereof
CN108315430B (zh) * 2018-04-28 2021-07-23 上海交通大学医学院附属仁济医院 Pdl1 snp基因型作为预测乳腺癌新辅助化疗疗效标记物的用途
WO2020151666A1 (zh) * 2019-01-25 2020-07-30 四川大学华西医院 血管瘤治疗的生物标记物
CN112941164A (zh) * 2021-01-27 2021-06-11 右江民族医学院附属医院 利用目标基因测序检测trpc6基因致病突变的方法
CN113502325A (zh) * 2021-07-02 2021-10-15 厦门市妇幼保健院（厦门市计划生育服务中心） 用于孕期铁营养缺乏风险评估检测试剂盒与应用方法
CN113945723B (zh) * 2021-10-28 2024-03-12 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2668212B1 (de) * 2011-01-28 2018-03-21 Sanofi Biotechnology Menschliche antikörper gegen psck9 zur verwendung in verfahren zur behandlung bestimmter gruppen von personen
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN111789944A (zh) * 2011-09-16 2020-10-20 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
CN106995822B (zh) * 2011-09-19 2021-06-29 科马布有限公司 定制供人类使用的抗体、可变结构域和链

Also Published As

Publication number Publication date
DE112014005747T5 (de) 2016-10-06
JP2017502030A (ja) 2017-01-19
CN106062004A (zh) 2016-10-26
JP2022000457A (ja) 2022-01-04
JP2020152729A (ja) 2020-09-24
JP7202431B2 (ja) 2023-01-11
DE112014005975T5 (de) 2016-09-15

Similar Documents

Publication Publication Date Title
US20230024543A1 (en) Methods of treating anaemia
US9109034B1 (en) Precision medicine by targeting PD-L1 variants for treatment of cancer
JP7202431B2 (ja) 対象とするヒト標的に特異的に結合するリガンド
US9067998B1 (en) Targeting PD-1 variants for treatment of cancer
US9062105B1 (en) Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8980273B1 (en) Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015092393A2 (en) Human targets
US8945560B1 (en) Method of treating rheumatoid arthritis using antibody to IL6R
WO2016071701A1 (en) Treatment of disease using ligand binding to targets of interest
US9017678B1 (en) Method of treating rheumatoid arthritis using antibody to IL6R
US8992927B1 (en) Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en) Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) Targeting human nav1.7 variants for treatment of pain
WO2016023916A1 (en) Treatment of disease using ligand binding to targets of interest
US9150660B1 (en) Precision Medicine by targeting human NAV1.8 variants for treatment of pain
TWI713444B (zh) 人類標靶
DE202014010421U1 (de) Menschliche Ziele
IES86644B2 (en) An injectable antibody preparation for use in treating or reducing the risk of rheumatoid arthritis
IES20140312A2 (en) An injectable antibody preparation for use in treating or reducing the risk of atopic dermatitis or asthma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200617

R150 Certificate of patent or registration of utility model

Ref document number: 6720079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250